(Alliance News) - AstraZeneca PLC on Tuesday said its reversal agent Ondexxya has been fully approved in Japan for reversal of acute major bleeds in some patients. Read More
(Alliance News) - AstraZeneca PLC said on Monday that its Evusheld antibody combination for Covid-19 prevention has been granted marketing authorization in the EU. Read More
(Alliance News) - Stock prices in London are seen opening ever-so slightly higher on Monday in a cautious start to the new week, with markets tracking geopolitical developments and rising Covid-19 cases in China, while also awaiting fresh drivers in a quiet day in the economic calendar. Read More
(Alliance News) - The EU's drug watchdog on Thursday recommended for approval AstraZeneca PLC's Covid-19 prevention cocktail, which can be used for patients with immune system problems or severe reactions to other coronavirus vaccines. Read More
(Alliance News) - The EU's drug watchdog on Thursday recommended for approval AstraZeneca's Covid-19 prevention jab, which can be used for patients with immune system problems or severe reactions to normal vaccines. Read More
(Alliance News) - AstraZeneca PLC on Thursday said that a Phase 3 trial for its immunotherapy Imfinzi did not achieve its primary endpoint in the treatment of patients with locally advanced cervical cancer. Read More
(Alliance News) - AstraZeneca PLC on Thursday said its Alexion subsidiary has reached a settlement agreement with Roche Holding AG's Chugai Pharmaceutical Co Ltd resolving all patent disputes between the two related to rare blood disease drug Ultomiris. Read More
(Alliance News) - AstraZeneca PLC and Merck & Co Inc on Wednesday said their jointly-developed Lynparza drug reduces the risk of death in a form of breast cancer. Read More
AstraZeneca PLC - Cambridge, England-based drugmaker - Says Lynparza treatment has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, who have already been treated with chemotherapy either before or after surgery. Read More
(Alliance News) - Hutchmed (China) Ltd on Monday said it has received USD15 million from AstraZeneca PLC as start-up activities for Saffron commenced. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday afternoon: Read More
(Alliance News) - AstraZeneca PLC said on Tuesday its rare disease group has closed an exclusive global collaboration to develop and commercialise an investigational human monoclonal antibody. Read More
(Alliance News) - Stock prices in London opened lower on Tuesday amid rising concerns over Russia's attack on Ukraine. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning: Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Non-Executive Chair Leif Johansson will retire at Astra's annual general meeting in 2023. It will hold its AGM this year on April 29, and Johansson will stand for election for one more year. Johansson joined the Astra board in 2012, so he reached the normal term limit of nine years last year. However, he was asked to stay on to oversee Astra's acquisition of the US's Alexion Pharmaceuticals, which is now completed. Senior Independent Non-Executive Director Philip Broadley is leading the search for a new chair. Read More
(Alliance News) - Worries over Ukraine dominated once more at the start of the week, with the FTSE 100's morning gains giving way to risk-off trade in the afternoon on doubts over a summit between Russia and the US. Read More
(Alliance News) - Stock prices in London turned lower at midday on Monday after conflicting statements about plans for a US-Russia summit to discuss Ukraine, dousing an earlier wave of optimism. Read More
(Alliance News) - AstraZeneca PLC said on Monday phase three trials for Enhertu showed positive outcomes in metastatic breast cancer patients and could "redefine how the disease is classified and treated". Read More